DRUG · Unmapped registry intervention
NT-I7
Find medicine records ·
Find other trials using this name
Clinical trial
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT04332653
Study summary
ClinicalTrials.govNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
pembrolizumab (KEYTRUDA®)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Any Advanced Solid Tumorsunresolved
Microsatellite Stable Colorectal Cancerunresolved
Ovarian Cancerverified · MONDO: ovarian cancer
Interventions
NT-I7DRUG
Sponsors & collaborators
NeoImmuneTechlead sponsor
Merck Sharp and Dohme LLC, Rahway, NJ, USAcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04332653 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.